The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
T-Rex study: Quality of life assessment using novel CTCAE-PRO and FKSI-19 in first-line treatment of metastatic renal cell carcinoma with tivozanib.
 
Viktor Grünwald
Stock and Other Ownership Interests - AstraZeneca; Bristol-Myers Squibb; Genmab; MSD; Seagen
Honoraria - Advanced Accelerator Applications/Novartis; Apogepha; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Janssen-Cilag; Merck Serono; MSD Oncology; Nanobiotix; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Cor2Ed; Cureteq; Debiopharm Group; Eisai; Gilead Sciences; Ipsen; Janssen-Cilag; MSD Oncology; Novartis; Oncorena; Onkowissen; PCI Biotech; Pfizer
Research Funding - Amgen (Inst); BMS (Inst); Gilead Sciences (Inst); Ipsen (Inst); MSD Oncology (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck Serono; Pfizer
 
Carsten Lange
No Relationships to Disclose
 
Carsten Ziske
No Relationships to Disclose
 
Miriam Hegemann
No Relationships to Disclose
 
Sandra Seseke
No Relationships to Disclose
 
Claus Fieseler
No Relationships to Disclose
 
Diana Standhaft
No Relationships to Disclose
 
Andreas Janitzky
No Relationships to Disclose
 
Martina Stauch
No Relationships to Disclose
 
Norbert Marschner
No Relationships to Disclose
 
Andrea Distelrath
No Relationships to Disclose
 
Martin Boegemann
Employment - Janssen; Janssen
Honoraria - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer/Vital; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Janssen-Cilag; Merck; MSD; Novartis; Pfizer; Roche; Sanofi/Aventis
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; ipsen; Janssen-Cilag; Merck; MSD; Novartis; Roche; Sanofi
Research Funding - IPSEN (Inst); Janssen-Cilag
Travel, Accommodations, Expenses - Amgen; Bayer; BMS GmbH & Co. KG; Janssen-Cilag
 
Olrik Rau
No Relationships to Disclose
 
Steffen Baumann
No Relationships to Disclose
 
Eva Hellmis
No Relationships to Disclose
 
Jan Dieckhoff
No Relationships to Disclose
 
Horst Brenneis
No Relationships to Disclose
 
Karen Rußwurm
No Relationships to Disclose
 
Philipp Ivanyi
Stock and Other Ownership Interests - BB Biotech Ventures
Honoraria - AIMM Therapeutics; Bayer/Vital; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck Serono; MSD Oncology; Roche Pharma AG
Consulting or Advisory Role - Bayer/Vital; Bristol-Myers Squibb; Eisai; Ipsen; Merck Serono; MSD; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen
Other Relationship - Merck Serono; Pfizer
 
Christian Doehn
No Relationships to Disclose